Hoth Therapeutics (HOTH) said Thursday that it entered into an exclusive patent license agreement with the US Department of Veterans Affairs to develop obesity treatment.
The deal also gives Hoth the rights to a patent co-developed by the department and Emory University, the company said.
Financial details weren't provided.
The technology uses the Glial Cell Line-Derived Neurotrophic Factor to treat obesity and related health conditions. The agreement includes a detailed development plan to guide the technology from research to commercialization, with the goal of making it widely accessible, the company said.
Shares of Hoth fell 6.3% in recent trading.
Price: 0.74, Change: -0.05, Percent Change: -6.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。